AngioSoma Valuation
| GSTC Stock | USD 0.0003 0.0001 50.00% |
AngioSoma seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of AngioSoma from analyzing the firm fundamentals such as return on asset of -44.28, and Shares Outstanding of 770.36 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that AngioSoma's price fluctuation is out of control at this time. Calculation of the real value of AngioSoma is based on 3 months time horizon. Increasing AngioSoma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since AngioSoma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AngioSoma Pink Sheet. However, AngioSoma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.0E-4 | Real 2.88E-4 | Hype 3.42E-4 |
The real value of AngioSoma Pink Sheet, also known as its intrinsic value, is the underlying worth of AngioSoma Company, which is reflected in its stock price. It is based on AngioSoma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of AngioSoma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of AngioSoma helps investors to forecast how AngioSoma pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AngioSoma more accurately as focusing exclusively on AngioSoma's fundamentals will not take into account other important factors: AngioSoma Total Value Analysis
AngioSoma is currently anticipated to have valuation of 9.39 M with market capitalization of 8.47 M, debt of 20 K, and cash on hands of 12. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the AngioSoma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.39 M | 8.47 M | 20 K | 12 |
AngioSoma Asset Utilization
One of the ways to look at asset utilization of AngioSoma is to check how much profit was generated for every dollar of assets it reports. AngioSoma shows a negative utilization of assets of -44.28 percent, losing $0.44 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of AngioSoma shows how unproductive it operates for each dollar spent on its assets.AngioSoma Ownership Allocation
AngioSoma holds a total of 770.36 Million outstanding shares. AngioSoma shows 10.02 percent of its outstanding shares held by insiders and 0.02 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.AngioSoma Profitability Analysis
Net Loss for the year was (1.49 M) with loss before overhead, payroll, taxes, and interest of (2.41 K).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates AngioSoma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in AngioSoma and how it compares across the competition.
About AngioSoma Valuation
The pink sheet valuation mechanism determines AngioSoma's current worth on a weekly basis. Our valuation model uses a comparative analysis of AngioSoma. We calculate exposure to AngioSoma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AngioSoma's related companies.GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. The company was incorporated in 2016 and is based in Richland, Washington. Globestar Therapeutics is traded on OTC Exchange in the United States.
8 Steps to conduct AngioSoma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates AngioSoma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct AngioSoma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain AngioSoma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine AngioSoma's revenue streams: Identify AngioSoma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research AngioSoma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish AngioSoma's growth potential: Evaluate AngioSoma's management, business model, and growth potential.
- Determine AngioSoma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate AngioSoma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
AngioSoma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 628.5 M | |
| Retained Earnings | -18.5 K |
Complementary Tools for AngioSoma Pink Sheet analysis
When running AngioSoma's price analysis, check to measure AngioSoma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioSoma is operating at the current time. Most of AngioSoma's value examination focuses on studying past and present price action to predict the probability of AngioSoma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AngioSoma's price. Additionally, you may evaluate how the addition of AngioSoma to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |